Veracyte, Inc. VCYT R2K
Healthcare · Diagnostics & Research · United States
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
READ MORE ›$46.34
+74.15% 1Y
Market & Price
Market Cap
$3.70B
Current Price
$46.34
High / Low (52W)
$49.38 / $23.03
Beta
1.89
Valuation
Stock P/E
42.91
Industry PE
23.65
Forward P/E
24.33
PEG Ratio
-
Book Value
$16.50
Price to Book
2.81
P/S
6.83
EV/EBITDA
31.65
Dividend Yield
-
Profitability & Returns
ROCE
5.07%
ROE
6.93%
ROA
3.76%
Profit Margin
16.25%
Op Margin
16.28%
EPS (Latest Qtr)
$0.35
EPS (TTM)
$1.08
Balance Sheet & Liquidity
Debt/Equity
2.93
Quick Ratio
8.72
Current Ratio
9.30
Debt
$39.33M
Total Assets
$1.41B
Current Assets
$488.38M
Working Capital
$428.44M
Ownership
Promoter Holding
0.51%
Chg in Prom Hold
-
FII / Inst Holding
113.29%
Chg in FII Hold
-0.00%
Financial Snapshot
Enterprise Value
$3.30B
Total Revenue (TTM)
$541.74M
EBITDA
$104.21M
Free Cash Flow
$104.51M
Operating Cash Flow
$166.16M
Shares Outstanding
79.79M
Gross Margin
72.91%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
20.37%
Profit 5Y
93.83%
Revenue (YoY)
21.50%
Earnings (YoY)
288.90%
PROS
- Compounding revenue at 20.4% over 5 years.
- Profit CAGR of 93.8% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VCYT Veracyte, Inc. R2K | 46.34 | 42.91 | $3.70B | - | 5.07% | 6.93% | 20.37% | 93.83% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 16.43M | 18.41M | 17.52M | 19.60M | 20.04M | 22.75M | 23.47M | 25.75M | 29.53M | 30.14M | 30.97M | 29.73M | 31.12M | 20.70M | 31.12M | 34.54M | 36.70M | 55.10M | 60.37M | 67.78M | 72.86M | 75.59M | 82.42M | 90.32M | 90.11M | 96.84M | 114.43M | - | - | 114.47M | 130.16M | 131.87M | 140.64M | 139.07M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.97M | 40.40M | 40.59M | 38.66M | 37.91M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.82M | 57.69M | 62.47M | 77.91M | - | - | 79.51M | 89.77M | 91.28M | 101.97M | 101.16M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 76.60M | 75.46M | 68.17M | 62.06M | 78.51M |
| Operating Income | -7.55M | -9.07M | -8.89M | -9.75M | -10.49M | -4.89M | -7.52M | -6.61M | -6.37M | - | -8.96M | -5.92M | -4.30M | - | -2.07M | -3.10M | -1.76M | - | -12.20M | -11.05M | -4.07M | - | -45.41M | -7.47M | -16.68M | -15.25M | -10.73M | -9.68M | -10.50M | -8.05M | -31.74M | -4.66M | 4.61M | - | - | 2.90M | 14.31M | 23.11M | 39.91M | 22.65M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.79M | 6.74M | 24.16M | 45.93M | 35.40M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.43M | 1.25M | 18.89M | 40.63M | 29.97M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 381.00K | 2.23M | -248.00K | -515.00K | 1.27M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.92M | -2.49M | -730.00K | -7.46M | -11.72M | -11.03M | -4.12M | -8.04M | -41.87M | -9.04M | -14.13M | -14.46M | -9.53M | -8.72M | -8.09M | -8.40M | -29.62M | -1.86M | 5.73M | - | - | 7.05M | -980.00K | 19.14M | 41.15M | 28.71M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.22 | -0.08 | - | -0.66 | -0.13 | -0.20 | -0.20 | -0.13 | -0.12 | -0.11 | -0.12 | -0.41 | -0.02 | 0.07 | - | - | 0.09 | -0.01 | 0.24 | 0.51 | 0.35 |
| R&D Expense | 2.79M | 3.10M | 3.56M | 3.46M | 4.27M | 4.01M | 4.03M | 3.60M | 3.05M | - | 3.67M | 4.60M | 3.42M | - | 3.44M | 3.33M | 3.64M | - | 4.41M | 4.17M | 4.04M | - | 5.34M | 6.25M | 8.01M | 9.17M | 9.38M | 10.77M | 12.77M | 12.54M | 13.32M | 15.96M | 16.46M | 17.57M | - | 17.72M | 16.26M | 15.98M | - | 27.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 65.08M | 71.95M | 92.01M | 120.37M | 117.48M | - | 296.54M | 361.05M | 445.76M | 517.14M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 120.86M | 131.37M | 147.62M | 154.61M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 175.68M | 229.68M | 298.14M | 362.53M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 211.02M | 247.13M | 278.63M | 284.25M |
| Operating Income | -15.27M | -18.93M | -23.17M | -29.01M | -33.47M | -28.80M | -26.54M | -22.23M | -15.13M | -35.39M | - | -35.34M | -17.45M | 19.51M | 78.28M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -10.30M | -49.41M | 49.20M | 89.62M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 198.00K | 15.00K | 2.00K | 1.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -36.43M | -76.61M | 25.74M | 68.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 133.00K | -2.21M | 1.61M | 1.85M |
| Net Income | - | - | - | - | - | - | - | -23.00M | -12.60M | -34.91M | - | -36.56M | -74.40M | 24.14M | 66.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.27 | -0.66 | - | -0.51 | -1.02 | 0.31 | 0.82 |
| R&D Expense | 6.68M | 6.61M | 7.81M | 9.80M | 12.80M | 15.32M | 13.88M | 14.82M | 14.85M | 17.20M | 29.84M | 40.60M | 57.30M | 69.29M | 70.81M |
Compounded Sales Growth
| 5 Years: | 20.37% |
| 1 Year: | 21.50% |
Compounded Profit Growth
| 5 Years: | 93.83% |
| 1 Year: | 288.90% |
Stock Price Performance
| 1 Year: | +74.15% |
| 6 Months: | -6.16% |
| 3 Months: | +26.65% |
| 1 Month: | +45.81% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 19.07M | 79.63M | 64.84M | 75.25M | 101.03M | 78.67M | 120.64M | 275.21M | 457.16M | - | 1.16B | 1.11B | 1.30B | 1.41B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 248.64M | 285.62M | 372.27M | 488.38M |
| Cash & Equivalents | 2.77M | 7.57M | 14.00M | 71.22M | 35.01M | 39.08M | 59.22M | 33.89M | 78.00M | 159.32M | 349.36M | - | 154.25M | 216.45M | 239.09M | 362.58M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 14.29M | 16.13M | 21.75M | 20.55M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 44.02M | 40.38M | 46.52M | 44.66M |
| Total Liabilities | - | - | 14.17M | 23.19M | 23.46M | 24.00M | 41.45M | 41.44M | 40.88M | 35.76M | 35.93M | - | 81.22M | 70.80M | 124.07M | 96.44M |
| Current Liabilities | - | - | 8.99M | 15.39M | 17.14M | 14.72M | 11.53M | 12.03M | 13.06M | 17.47M | 16.78M | - | 62.61M | 61.24M | 78.63M | 59.94M |
| Long Term Debt | - | - | - | 4.90M | 4.92M | 4.99M | 24.92M | 24.94M | 23.93M | 694.00K | 810.00K | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 14.72M | 12.63M | 50.74M | 39.65M |
| Total Equity | -26.81M | -40.77M | -58.47M | 56.44M | 41.37M | 51.25M | 59.58M | 37.23M | 79.75M | 239.46M | 421.23M | - | 1.08B | 1.04B | 1.18B | 1.31B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 71.96M | 73.26M | 77.77M | 79.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -26.96M | -27.98M | -23.91M | -13.52M | -3.23M | -9.71M | - | 7.54M | 44.22M | 75.10M | 136.31M |
| Investing Cash Flow | - | - | - | - | -6.70M | -4.21M | -1.31M | -1.87M | -42.73M | -3.84M | - | -29.39M | 15.11M | -56.27M | -9.21M |
| Financing Cash Flow | - | - | - | - | 37.73M | 52.33M | -218.00K | 59.50M | 127.29M | 203.59M | - | 3.49M | 2.84M | 4.90M | -4.22M |
| Capital Expenditure | -276.00K | -1.46M | -1.33M | -2.02M | -6.17M | -4.21M | -1.75M | -1.87M | -2.76M | -2.84M | - | -8.55M | -9.96M | -11.29M | -9.68M |
| Free Cash Flow | - | - | - | - | -33.13M | -32.19M | -25.67M | -15.39M | -5.99M | -12.55M | - | -1.01M | 34.26M | 63.81M | 126.63M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -18.36M | 62.17M | 23.73M | 122.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 59.2% | 63.6% | 66.9% | 70.1% |
| Operating Margin % | - | - | - | - | - | -44.3% | -36.9% | -24.2% | -12.6% | -30.1% | - | -11.9% | -4.8% | 4.4% | 15.1% |
| Net Margin % | - | - | - | - | - | - | - | -25.0% | -10.5% | -29.7% | - | -12.3% | -20.6% | 5.4% | 12.8% |
| ROE % | - | - | - | - | - | - | - | -28.8% | -5.3% | -8.3% | - | -3.4% | -7.1% | 2.1% | 5.1% |
| ROCE % | - | -187.9% | -36.1% | -60.8% | -55.3% | -32.2% | -39.8% | -20.7% | -5.9% | -8.0% | - | -3.2% | -1.7% | 1.6% | 5.8% |
Shareholding Pattern
Insiders
0.51%
Institutions
113.29%
Public Float
113.87%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.51% | 13.17M | $610.42M |
| 2 | FMR, LLC | 9.73% | 7.76M | $359.78M |
| 3 | Artisan Partners Limited Partnership | 6.89% | 5.50M | $254.70M |
| 4 | State Street Corporation | 6.32% | 5.04M | $233.72M |
| 5 | Vanguard Portfolio Management LLC | 5.57% | 4.44M | $205.97M |
| 6 | Vanguard Capital Management LLC | 4.43% | 3.53M | $163.68M |
| 7 | ARK Investment Management, LLC | 3.83% | 3.05M | $141.51M |
| 8 | Dimensional Fund Advisors LP | 3.61% | 2.88M | $133.51M |
| 9 | Wellington Management Group, LLP | 3.21% | 2.56M | $118.55M |
| 10 | First Trust Advisors LP | 2.65% | 2.12M | $98.10M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VCYT
No recent headlines available.